Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Major depressive disorders are real public health issues in terms of diagnosis and treatment. Some forms of depression are chronic and resistant to treatment (TRD). In these forms suicide risk is important.
Patients with TRD are potential candidates for neurosurgical interventions to treat depression. However, psychosurgery interventions based upon lesions, showed their limitations related to 1. the large variability in neurosurgical gestures, 2. their side effects, and of course 3. the irreversible damage caused by the surgery.
Thus, deep brain stimulation (DBS) could represent an opportunity for patients suffering from TRD. Our preliminary study based upon the stimulation of the accumbens nucleus showed encouraging results. The investigators have thus planned a randomized controlled trial versus sham stimulation to confirm the therapeutic value of nucleus accumbens DBS.
Because of their recurrent nature, their prevalence and their consequences, major depressive disorders are real public health issues in terms of diagnosis and treatment.
Some forms of depression are chronic and resistant to treatment (TRD), either unipolar (repeated episodes of depression) or bipolar (repeated episodes of depression and manic and/or hypomanic episodes). In these forms suicide risk is important.
Patients with TRD are potential candidates for neurosurgical interventions to treat depression. The benefit of neurosurgical procedures is expected to be important in these patients.
Psychosurgery interventions based upon lesions, however, showed their limitations related to 1/ the large variability in neurosurgical gestures, 2/ their side effects, and of course 3/ the irreversible damage caused by the surgery.
Current brain imaging data yielded fresh information about the pathophysiology of depression and suggested new therapeutic approaches in TRD.
Modulation of sub-caudate specific pathways, which are part of orbitofrontal and anterior cingulate cortico-subcortical loops should allow for a diminution of depressive symptoms.
The modulation of these specific pathways, initially targeted by classical neurosurgery, could benefit from current developments in functional neurosurgery.
Deep brain stimulation (DBS) may represent an opportunity for patients suffering from TRD. Our preliminary study based upon the stimulation of the accumbens nucleus showed encouraging results. The investigators have thus planned a randomized controlled trial versus sham stimulation to confirm the therapeutic value of nucleus accumbens DBS.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| DBS | Experimental | The medical device includes:
The target is the Accumbens nucleus. The two electrodes are implanted in a single session under local anaesthesia or intermittent sedation (propofol parenteral without intubation early intervention). Day 0 is defined by the surgery. The DBS is "on" during 6 months (between Month 1 and Month 7). Stimulation will also be on after Month 7. |
|
| SHAM | Sham Comparator | The medical device includes:
The target is the Accumbens nucleus. The two electrodes are implanted in a single session under local anaesthesia or intermittent sedation (propofol parenteral without intubation early intervention). Day 0 is defined by the surgery. The DBS is "off" during 6 months (between Month 1 and Month 7). Possibility to active the stimulation after Month 7. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| DBS | Device |
| ||
| SHAM | Device |
| Measure | Description | Time Frame |
|---|---|---|
| Response = 50 % decrease of the HDRS-17 (Hamilton depression rating scale, 17 items version) (yes/no) | Response is defined as a 50 % decrease of the HDRS-17 (Hamilton depression rating scale, 17 items version) | Month 7 |
| Measure | Description | Time Frame |
|---|---|---|
| Remission (yes/no) | Remission is defined as an HDRS-17 score < 7 | Month 7 |
| CGI (Clinical global impressions) amelioration (yes/no) | Score of 1 or 2 (item 2 of the CGI) |
| Measure | Description | Time Frame |
|---|---|---|
| HDRS-17 (Hamilton depression rating scale, 17 items version) | Longitudinal evolution of the score | Month -3 ; Month -1; Day -7; Day 15; Month 1; Day 45; Month 2 ; Day 75 ; Month 3; Month 4; Month 5; Month 6; Month 7; Month 8; Month 9; Month 10; Month 13; Month 16; Month 19; Month 22; Month 24 |
| MADRS (Montgomery-Asberg Depression Rating Scale) |
Inclusion Criteria:
Age between 18 and 70 years
DSM-IV (DSM = Diagnostic and Statistical Manual) criteria for a recurrent depressive disorder or bipolar disorder
Duration of the episode > 2 years
Severity of the episode attested by :
Persistence of severity criteria during the screening
Following characteristics resistance in case of recurrent depressive disorder :
Following characteristics of resistance in case of bipolar disorder:
Understanding the conduct of the study
Giving a written informed consent
Benefiting from the french social insurance
Non-Inclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Jean Michel Reymann | CIC INSERM 0203 CHU Rennes | Study Chair |
| Florian Naudet | CIC INSERM 0203 CHU Rennes | Study Chair |
| Bruno Millet | Groupe Hospitalier Pitie-Salpetriere | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| APHM | Marseille | France | ||||
| APHP Pitié Salpetriere |
| Type | Date | Date Unknown |
|---|---|---|
| Release | Feb 8, 2024 | |
| Reset | Aug 5, 2024 |
Not provided
Not provided
| Release Date | Unrelease Date | Unrelease Date Unknown | Reset Date | MCP Release Number |
|---|---|---|---|---|
| Feb 8, 2024 | Aug 5, 2024 |
| ID | Term |
|---|---|
| D003865 | Depressive Disorder, Major |
| D003866 | Depressive Disorder |
| D001714 | Bipolar Disorder |
| ID | Term |
|---|---|
| D019964 | Mood Disorders |
| D001523 | Mental Disorders |
| D000068105 | Bipolar and Related Disorders |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Month 7 |
| GAF (Global assessment of functioning) | Presence of a score ≥ 60 | Month 7 |
| HDRS-17 (Hamilton depression rating scale, 17 items version) | Score | Month 7 |
| MADRS (Montgomery-Asberg Depression Rating Scale) | Score | Month 7 |
| BDI (Beck Depression Inventory) | Score | Month 7 |
| CGI (Clinical global impressions) | Score | Month 7 |
| LARS (Lille Apathy Rating scale) | Score | Month 7 |
| GAF (Global assessment of functioning) | Score | Month 7 |
| Neuropsychological assessment | Day -7 ; Month 1; Month 7; Month 13; Month 19; Month 24 |
| Cerebral metabolism (PET scans) | Day -7; Month 7 |
| Adverse events | Adverse events occuring during the study. | Month 24 |
Longitudinal evolution of the score |
| Month -3 ; Month -1; Day -7; Day 15; Month 1; Day 45; Month 2 ; Day 75 ; Month 3; Month 4; Month 5; Month 6; Month 7; Month 8; Month 9; Month 10; Month 13; Month 16; Month 19; Month 22; Month 24 |
| BDI (Beck Depression Inventory) | Longitudinal evolution of the score | Day -7; Day 15; Month 1; Day 45; Month 2 ; Day 75 ; Month 3; Month 4; Month 5; Month 6; Month 7; Month 8; Month 9; Month 10; Month 13; Month 16; Month 19; Month 22; Month 24 |
| CGI (Clinical global impressions) | Longitudinal evolution of the score | Month -3 ; Month -1; Day-7; Day15; Month 1; Day 45; Month 2 ; Day 75 ; Month 3; Month 4; Month 5; Month 6; Month 7; Month 8; Month 9; Month 10; Month 13; Month 16; Month 19; Month 22; Month 24 |
| LARS (Lille Apathy Rating scale) | Longitudinal evolution of the score | Day -7; Month 1; Month 7; Month 13; Month 19; Month 24 |
| GAF (Global assessment of functioning) | Longitudinal evolution of the score | Month -3 ; Month -1; Day -7; Month 1; Month 7; Month 13; Month 19; Month 24 |
| YMRS (Young Mania Rating Scale) | Longitudinal evolution of the score | Day -7; Month 1; Month 7; Month 13; Month 19; Month 24 |
| MATHYS (Multidimensional Assessment of Thymic States) | Longitudinal evolution of the score | Day -7; Month 1; Month 7; Month 13; Month 19; Month 24 |
| Response (50 % decrease of the HDRS-17) | During the whole follow up | Month 24 |
| Remission | During the whole follow up Remission is defined as an HDRS-17 score < 7 | M24 |
| Paris |
| France |
| CHS | Poitiers | France |
| CHS | Rouen | France |
| CHU | Toulouse | France |